Background: There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinical outcomes of tuberculosis (TB) treatment. We explored the effects of DIH on the clinical course and outcomes of pulmonary TB. Methods: In this retrospective cohort study, we included patients with culture-proven pulmonary TB treated in a tertiary hospital from 2013 to 2016 The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamid The risk of anti-TB drug induced hepatotoxicity is higher in patients with chronic hepatitis B virus (HBV) patients compared to uninfected subjects (16% vs 4.7% p < 0.001) and the severity was much higher in the HBV patients in this study (4.7% vs 2.5% p < 0.001). 86 Studies also have shown that the severity of the hepatotoxicity is directly. There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinical outcomes of tuberculosis (TB) treatment. We explored the effects of DIH on the clinical course and outcomes of pulmonary TB. In this retrospective cohort study, we included patients with culture-proven pulmonary TB treated in a tertiary hospital from 2013 to 2016
therapy. Commonly used drugs are Isoniazid, Rifampicin, pyrazinamide and Ethambutol. All these drugs are used in combination for a few months (2-6 months). According to a study, the incidence of drug in-duced liver injury in India is between 8-36%. Incidence of drug induced hepatotoxicity is higher in Asian countries due to ethnic suscep The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study Jin Hwa Song1, Seo-Young Yoon2, Tae Yun Park2, Eun Young Heo2, Deog Kyeom Kim2, Hee Soon Chung2 and Jung-Kyu Lee2* Abstract Background: There are limited data available on whether drug-induced hepatotoxicity (DIH) affects the clinica The exact mechanism of antituberculosis drug-induced hepatotoxicity is unknown, but toxic metabolites are suggested to play a crucial role in the development, at least in the case of isoniazid. Priorities for future studies include basic studies to elucidate the mechanism of antituberculosis drug-induced hepatotoxicity, genetic risk factor. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One. 2013; 8 :e64622. doi: 10.1371/journal.pone.0064622
. Agha, Ibraheim I. El-Mahalawy, Hosam M. Seleem and Mohamed A. Helwa, Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity, Egyptian Journal of Chest Diseases and Tuberculosis, 64, 1, (91), (2015) The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: A case control study Jin Hwa Song, Seo Young Yoon, Tae Yun Park , Eun Young Heo , Deog Kyeom Kim , Hee Soon Chung , Jung Kyu Le
. Introduction. Hepatotoxicity is a frequent and potentially serious adverse effect of standard first line anti-tuberculosis drug (ATD) regimens containing the hepatotoxic compounds isoniazid, rifampicin, and pyrazinamide. There is a wide variety in the reported incidence of ATD-induced liver injury in different studies (2% to 28%) Drug-Induced Hepatotoxicity: A Review Aashish Pandit, Tarun Sachdeva and Pallavi Bafna ABSTRACT Liver is the principle organ for maintaining the body's internal environment. There is currently no way to reimburse for the absence of liver function. Its major influence is on the important cause of liver injury
Hassen Ali A, Belachew T, Yami A, Ayen WY. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One. 2013;8(5):e64622. 30 Drug-induced liver injury (DILI) secondary to antituberculous treatment (ATT) is reported in 2-28% of patients [1, 2] varying with the definition, study population and treatment regimen.Risk factors associated with this potentially fatal complication include co-infection with HIV, hepatitis B or C, pre-existing chronic liver disease, high alcohol intake, malnutrition, advanced age, female. Background. Anti-tuberculosis drug induced hepatotoxicity (ATDH) is a major adverse drug reaction associated for anti-tuberculosis therapy. The glutathione S-transferases (GST) plays a crucial role in the detoxification of hepatotoxic metabolites of anti-tuberculosis drugs.An association between GSTM1/GSTT1 null mutations and increased risk of ATDH has been demonstrated in adults The median interval from treatment initiation drugs was associated with higher rate of hepatotoxicity of drug to development of clinical symptoms is 16 weeks (OR 2.6) when compared to each drug on its own.26 Daily (range 6 weeks-6 months).11-13 Anti-TB drug induced ful- dosing regimens haven't been shown to be associated minant liver.
Background This study was carried out to determine the incidence and predictors of anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia. Methods/Principal Findings A nested case-control study was conducted by reviewing charts of all TB/HIV co-infected patients who commenced anti-TB treatment from January 2008 to December 2011 at. Here, we report a case of a pediatric patient affected by nodal tuberculosis and treated with INH, who developed hepatotoxicity during therapy. Analysis of INH plasma concentrations by LC-MS/MS confirmed the presence of drug toxic levels, and NAT2 gene sequencing analysis revealed the NAT2∗5C/∗6B slow metabolizer haplotype A nested case-control study was conducted in order to examine whether dosing schedules of standard pyrazinamide-containing anti-tuberculosis (TB) treatment (standard treatment) might affect hepatotoxicity. The present authors retrospectively identified all patients with hepatitis using biochemical criteria from a cohort of 3,007 clinic patients who commenced anti-TB treatment from January 1. Several retrospective studies and reviews with methodologic limitations suggest that the severity of isoniazid-induced hepatotoxicity, when it does occur, may be worse in women. In the USPHS study ( 63 ), there were 8 deaths among 13,838 enrolled subjects (0.57 per 1,000 treated), 5 of which were in African-American women, with 7 of 8 deaths.
Anti-tuberculosis drug-induced hepatotoxicity is a common serious adverse drug reaction. This study intended to determine the prevalence and associated factors of drug-induced hepatotoxicity among tuberculosis and human immunodeficiency virus co-infected patients in Dessie referral hospital northeast Ethiopia. In this cross-sectional study 84 patients were enrolled retrospectively However, a variety of adverse drug reactions (ADRs) may occur during long-term multi-drug combination therapy, among which anti-tuberculosis drug-induced hepatotoxicity (ATDH) is the most common and most harmful and is also one of the common causes of drug-induced liver injury (DILI) in China (Shen et al., 2019) The most common adverse effect leading to interruption of therapy is hepatotoxicity . Anti-TB drug-induced hepatotoxicity (DIH) is associated with a mortality of 6%-12% if these drugs are continued after the onset of symptoms . The risk of hepatotoxicity is increased when the drugs are combined Background: Drug-induced liver injury (DILI) is a well-recognized adverse event of anti tuberculosis drugs (ATD) possibly associated with genetic variations. The objective of this study was to perform genome-wide association study (GWAS) to identify genetic variants associated with the risk for ATD induced liver toxicity in Ethiopian patients Men's grooming made easy - top quality grooming essentials for every price range. Explore Hanz De Fuko, Regenerate, Jack Black, Bull Dog and other Mankind favourites
Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome, DARU Vol. 17, No. 3 2009. 8. Alladi Mohan et.at. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity, Indian J Med Res 132, July 2010, pp 81-6. 9 lence of drug-induced hepatitis, a nested case- control study was conducted in order to examine whether dosing schedules of standard pyrazinamide-containing anti-TB treatment might affect hepatotoxicity in the first 9 weeks. MATERIAL AND METHODS A nested case-control study was conducted in order to examine the impact of dosing schedule ABSTRACT. Hepatotoxicity due to antituberculosis drugs limits treatment in patients coinfected with HIV and tuberculosis. We conducted a case-control study to identify risk factors for hepatotoxicity among patients coinfected with tuberculosis and HIV in two hospitals in Recife, Pernambuco State, Brazil Background: Antituberculosis (ATT) drug-induced liver injury (DILI) is a common and serious adverse effect of tuberculosis (TB) treatment. This retrospective study was carried out to study the prev.. Silymarin may prevent anti‐tuberculosis drug‐induced liver injury Silymarin may prevent anti‐tuberculosis drug‐induced liver injury Kraft, K 2016-06-01 00:00:00 108 Focus on Alternative and Complementary Therapies June 2016 21(2) DOI 10.1111/fct.12260 Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A
DILI-Drug-induced liver injury DILIN - Drug-induced liver injury IDW- ideal body weight mtDNA- Mitochondria DNA SGPT-Serum glutamic pyruvic transaminase REFERENCE 1. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 2006; 174: (pg. 935 -52). 2 A haplotype consisting of several SNPs in the TXNRD1 gene is associated with the development of drug-induced liver injury, including injury caused by anti-tuberculosis drugs, antibiotics, and antiepileptic drugs in a Korean population [ 91 ]. Another study conducted in a Chinese population also found association between a haplotype involving. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis; Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis. Authors . Laghari Madeeha Talpur, Bandeh, Ali Sulaiman, Syed, Azhar Syed Khan, Amer Hayat Bhatti, Zohra Affiliation However, drug-induced liver injury (DILI) associated with the above medications is a common adverse drug reaction. Hepatotoxicity is likely to develop further severely when used in combination, especially on the addition of pyrazinamide [Reference Sharma 7- Reference Lin 9]. Thus, anti-TB DILI would result in the interruption of chemotherapy.
Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is the most frequent, and potentially fatal adverse effect in the treatment of tuberculosis (TB). The rs7574865 polymorphism in the signal transducer and activator of transcription 4 gene (STAT4) was reported to be associated with drug-induced liver injury. However, there was no study aimed to this association in Chinese patients. The aim of. Ant tuberculosis drug-induced liver injury creates obstacles in treatment and also exerts socioeconomic strain on resources. Objective: To determine the frequency, severity and pattern of the Anti-tuberculosis Drug-Induced Liver Injury in children under 14 years of age. Study Design: Case series study. Duration of Study: 02-10-2015 to 03-10-2016 The most reliable liver safety signal in a clinical trial is considered to be 'Hy's Law cases' defined as subjects experiencing hepatocellular injury and serum bilirubin elevations with no more likely cause than study drug. However, there is little published data to support the current biochemical criteria for Hy's Law cases or their use to estimate postmarketing risk of severe liver.
Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study Miaomiao Yang , Hongqiu Pa (2017) Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: A Chinese population-based prospective case-control study. Clinical Drug Investigation 37: 1125 - 1136 Title: Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran VOLUME: 6 ISSUE: 1 Author(s):Hossein Khalili, Shamileh Fouladdel, Mohammad Sistanizad, Mahboobeh Hajiabdolbaghi and Ebrahim Azizi Affiliation:Faculty of Pharmacy, Tehran University of Medical Sciences, P.O. Box: 14155/6451, Postal Code:1417614411, Tehran, Iran Title:Evaluation of Risk Factors for Development of Anti-Tubercular Therapy Induced Hepatotoxicity: A Prospective Study VOLUME: 15 ISSUE: 3 Author(s):Malladi V.S. Subbalaxmi, Radhika Soanker* and Arivittur V. Lakshmi Affiliation:Department of General Medicine, Nizam's Institute of Medical Sciences, Hyderabad, Department of Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical.
The first line drugs used to treat TB were isoniazid (INH), rifampicin (RIF), pyrazinamide (PZY) and ethambutol (EMB). Most of the TB patients tolerate the drugs but some develop hepatotoxicity known as anti-tuberculosis drug-induced liver injury (ATLI). [Forget 2006].The ATLI ranges from mild to severe forms, and can even be fatal Sharma SK, Jha BK, Sharma A, et al. Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2014;18:588-93. Brito TC, Possuelo LG, Valim ARM, et al. Polymorphisms in CYP2E1, GSTM1 and GSTT1 and anti-tuberculosis drug-induced hepatotoxicity Tuberculosis is a major health burden in developing countries like India. India accounts for one-fourth of world's TB burden. Annual incidence rate of TB in India is around 2 million and around 300,000 deaths occur due to TB every year. AT This may sometimes require interruption of therapy with anti-TB drugs. Incidence of hepatotoxicity during treatment of TB disease varies from 5 to 33 %. It depends on the study population, definition of hepatotoxicity, anti-TB drugs used, and the way of monitoring (Reference Saukkonen, Cohn and Jasmer 1). Many factors have been associated with DIH
Between October 2007 and June 2008, a cohort of Anti-tuberculosis Drugs induced Adverse Reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS) was established by us in China.18 Based on this cohort, ADRs and genetic susceptibility in anti-TB treatment patients were widely studied,8 19-23 which made a great. The study subjects were predominantly males 146 (76.8%) than females 44 (23.2%). Drug-induced hepatotoxicity with anti-tuberculosis drugs was observed the most among Chinese 90 (47%) ethnicity. Eighty-five (72%) male and 33 female (28%) tuberculosis drug-induced (TB-DIH) patients had a successful treatment outcome (2007). SY: [Systematic review of anti-tuberculosis drug induced adverse reactions in China]. Zhonghua Jie He He Hu Xi Za Zhi (1996). Tandon RK: Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study
Drug-induced liver disease has been reported to occur in 1 in 10,000 to 1 in 100,000 patients for any given drug, yet its true incidence is likely much higher. Anti-tuberculosis drugs (INH. Abstract: The present study was aimed to investigate the protective effect of Piperbetle against nonsteroidal anti- inflammatory drug (NSAID)-induced gastric ulcer in the male albino rats. Piper betle (0, 50, 100 and 200 mg/kg bwt) was given for 15 consecutive days Schizophrenia (SCZ) may cause tuberculosis, the treatments for which can induce anti-tuberculosis drug-induced hepatotoxicity (ATDH) and SCZ-like disorders. To date, the causal genes of both SCZ. Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is one of the most prevalent and serious adverse drug reactions in the course of anti-tuberculosis (TB) treatment. Some researchers suggested that determination of N-acetyltransferase 2 (NAT2) genotype may be clinically useful to identify patients at high risk of developing ATDH. Aim
Meanwhile, unlike the concentrations of INH or other drugs, the metabolic ratio of plasma acetyl-INH to INH levels 2 hr after drug ingestion was significantly lower (P<0.001). in the hepatotoxicity group than in the non-hepatotoxicity group in the present study. This result suggests that the serum slow acetylator status of INH may be a risk. Peran curcumin dalam penatalaksanaan drug induced liver injury (DILI) mulai banyak dipelajari. Curcumin diduga memiliki efek terhadap modulasi mediator inflamasi, stres oksidatif, dan senyawa antioksidan di dalam sel hepar, sehingga memungkinkan untuk menjadi terapi dalam perbaikan seluler pasca cedera hepatosit
Drug-induced liver injury (DILI) is a known adverse effect of both anti-tuberculosis (anti-TB) and antiretroviral (ARV) drugs. Recent studies highlight the implications of genetic predispositions to DILI. We performed a case-control study to identify Human Leukocyte Antigen-B (HLA-B) variant alleles associated with anti-TB and ARV co-treatment induced liver toxicity in Ethiopian TB and HIV co. Drug-induced liver injury (DILI) is a problem of increasing significance, but has been a long-standing concern in the treatment of tuberculosis (TB) infection. The liver has a central role in drug metabolism and detoxification, and is consequently vulnerable to injury Background: Antituberculosis (ATT) drug-induced liver injury (DILI) is a common and serious adverse effect of tuberculosis (TB) treatment. This retrospective study was carried out to study the prevalence of DILI among patients who had received anti-TB medications and to study some of the known risk factors responsible for causing DILI
Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study. Journal of clinical pharmacy and therapeutics 44 , 534-542. Abstract: Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis. However, PZA is hepatotoxic and the underlying mechanisms are poorly understood. Biotransformation of PZA in the liver was primarily suggested behind its hepatoxicity Purpose: The goals of this study were to identify the frequency of N-acetyltransferase-2 genotypes and phenotypes in Iranian tuberculosis and healthy subje.. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. The International Journal of Tuberculosis and Lung Disease, 2014. Anju Sirohiwal. Thirumurthy Velpandian. S. Sharma. S. Sinha. Govind Makharia. Govind Makharia. Govind Makharia. Sundararajan Singh Drug-induced hepatotoxicity or drug-induced liver injury (DILI) is an acute or chronic response to a natural or manufactured compound.  DILI can be classified based on clinical presentation (hepatocellular, cholestatic, or mixed), mechanism of hepatotoxicity, or histological appearance from a liver biopsy
Drugs with direct toxic effects on myeloid precursors include ticlopidine, bulsufan, methamizole, ethosuximide, and chlo-rpromazine. Imputability of anti-tuberculosis treatment in neutropenia In a review of literature, authors reported that the incidence rate of agranulocytosis due to anti-tuberculosis drugs was esti-mated at 0.06% [2,3] Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. rifampicin and pyrazinamide which are essential first- Risk factors for hepatotoxicity from anti-tuberculosis drugs: a line anti-TB drugs, in the light that acute hepatitis was case control study. Thorax 1996; 51 : 132-6. not due to anti-TB drugs. 4 Tuberculosis (TB) is still a major public health problem in Indonesia. Anti-tuberculosis drug-induced hepatotoxicity (DIH) is common side effect leading to changes in treatment regimens, and the less effective second-line treatments.Several risk factors such as age, sex, body mass index (BMI) and acetylization status for hepatotoxicity were suggested in previous studies but in the fact, those.
Background Drug-induced liver injury (DILI) is a well-recognized adverse event of anti tuberculosis drugs (ATD) possibly associated with genetic variations. The objective of this study was to perform genome-wide association study (GWAS) to identify genetic variants associated with the risk for ATD induced liver toxicity in Ethiopian patients. Result Treatment-naïve newly diagnosed. Drug-induced liver injury (DILI) is a known adverse effect of both anti-tuberculosis (anti-TB) and antiretroviral (ARV) drugs. Recent studies highlight the implications of genetic predispositions to DILI. We performed a case-control study to identify Human Leukocyte Antigen-B (HLA-B) variant alleles associated with anti-TB and ARV co-treatment induced liver toxicity in Ethiopian TB and HIV co.
Prevalence and risk factors of anti- tuberculosis drug-induced hepatitis in Malaysia Marzuki O A, Fauzi A R M, Ayoub S, Kamarul Imran M. Said Fauzie. Download PDF. Download Full PDF Package. This paper. A short summary of this paper. 37 Full PDFs related to this paper. READ PAPER In the Western world, drug-induced liver injury (DILI) now accounts for the majority of acute liver failure cases. 1, 2 It is also responsible for the market withdrawal or restricted use of many drugs, and is therefore a major concern to the healthcare and pharmaceutical industries. 3-5 The liver plays a crucial role in determining the toxicity of drugs due to its key role in the metabolism. Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is one of the leading adverse drug reactions during the course of tuberculosis treatment and poses a considerable challenge to clinicians and researchers. Previous studies have revealed the important contribution of drug metabolism and transporter enzymes to the complexity of ATDH. The emerging roles of immune response and oxidative stress.